{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:21:10Z","timestamp":1791404470033,"version":"4.3.3"},"reference-count":158,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/100018512","name":"UHK PrF Excellence project","doi-asserted-by":"publisher","award":["2208\/2023-2024"],"award-info":[{"award-number":["2208\/2023-2024"]}],"id":[{"id":"10.13039\/100018512","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health","award":["NV19-09-00578"],"award-info":[{"award-number":["NV19-09-00578"]}]},{"DOI":"10.13039\/100019624","name":"MH CZ - DRO","doi-asserted-by":"publisher","award":["UHHK"],"award-info":[{"award-number":["UHHK"]}],"id":[{"id":"10.13039\/100019624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019624","name":"MH CZ - DRO","doi-asserted-by":"publisher","award":["00179906"],"award-info":[{"award-number":["00179906"]}],"id":[{"id":"10.13039\/100019624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP2023R35"],"award-info":[{"award-number":["RSP2023R35"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy\nand radiation therapy. The phosphatidylinositol-3-kinase\/ protein kinase B \/mammalian target\nof rapamycin (PI3K\/Akt\/mTOR) signaling pathway has emerged as a critical cancer target due\nto its central role in regulating key cellular processes such as cell growth, proliferation, survival, and\nmetabolism. Dysregulation of this pathway has been implicated in the development and progression\nof bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K\/Akt\/mTOR inhibitors have shown\npromising preclinical and clinical activity in various cancers. These agents can inhibit the activation\nof PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor\ngrowth and survival. In addition, PI3K\/Akt\/mTOR inhibitors have been shown to enhance the efficacy\nof other anticancer therapies, such as chemotherapy and radiation therapy. The different types\nof PI3K\/Akt\/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be\neffective depending on the specific sarcoma type and stage. The molecular targeting of\nPI3K\/Akt\/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived\nmolecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K\/mTOR inhibitors have\nbeen delineated. While there are still challenges to be addressed, the preclinical and clinical evidence\nsuggests that these inhibitors may significantly improve patient outcomes. Further research is\nneeded to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing\nmore selective and effective agents to meet the clinical needs of sarcoma patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113895575270904231129062137","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T12:44:45Z","timestamp":1706100285000},"page":"1496-1520","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeted Inhibition of the PI3K\/Akt\/mTOR Signaling Axis: Potential for\nSarcoma Therapy"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8820-1231","authenticated-orcid":true,"given":"Atif Khurshid","family":"Wani","sequence":"first","affiliation":[{"name":"School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Singh","sequence":"additional","affiliation":[{"name":"School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Akhtar","sequence":"additional","affiliation":[{"name":"School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-0457","authenticated-orcid":true,"given":"Ajit","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-246X","authenticated-orcid":true,"given":"Eugenie","family":"Nepovimova","sequence":"additional","affiliation":[{"name":"Department\nof Chemistry, Faculty of Science, University of Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Oleksak","sequence":"additional","affiliation":[{"name":"Department\nof Chemistry, Faculty of Science, University of Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Chrienova","sequence":"additional","affiliation":[{"name":"Department\nof Chemistry, Faculty of Science, University of Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suliman","family":"Alomar","sequence":"additional","affiliation":[{"name":"King Saud University, Zoology\nDepartment, College of Science, Riyadh, 11451, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Chopra","sequence":"additional","affiliation":[{"name":"School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9664-1109","authenticated-orcid":true,"given":"Kamil","family":"Kuca","sequence":"additional","affiliation":[{"name":"Department\nof Chemistry, Faculty of Science, University of Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czechia"},{"name":"Biomedical Research Center, University Hospital\nHradec Kralove, Hradec Kr\u00e1lov\u00e9, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","volume":"113","author":"Sbaraglia M.","year":"2020","unstructured":"Sbaraglia M.; Bellan E.; Dei Tos A.P.; The 2020 WHO classification of soft tissue tumours: News and perspectives. Pathologica  2020,113(2),70-84","journal-title":"Pathologica"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.mcp.2022.101850","volume":"65","author":"Raza S.H.A.","year":"2022","unstructured":"Raza S.H.A.; Pant S.D.; Wani A.K.; Mohamed H.H.; Khalifa N.E.; Almohaimeed H.M.; Alshanwani A.R.; Assiri R.; Aggad W.S.; Noreldin A.E.; Abdelnour S.A.; Wang Z.; Zan L.; Kr\u00fcppel-like factors family regulation of adipogenic markers genes in bovine cattle adipogenesis. Mol Cell Probes  2022,65,101850","journal-title":"Mol Cell Probes"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.14670\/HH-29.127","volume":"29","author":"Lee S.E.","year":"2014","unstructured":"Lee S.E.; Kim Y.J.; Kwon M.J.; Choi D.I.; Lee J.; Cho J.; Seo S.W.; Kim S.J.; Shin Y.K.; Choi Y-L.; High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. Histol Histopathol  2014,29(1),127-138","journal-title":"Histol Histopathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cancergen.2017.09.005","volume":"218-219","author":"Ricciotti R.W.","year":"2017","unstructured":"Ricciotti R.W.; Baraff A.J.; Jour G.; Kyriss M.; Wu Y.; Liu Y.; Li S.C.; Hoch B.; Liu Y.J.; High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. Cancer Genet  2017,218-219,69-80","journal-title":"Cancer Genet"},{"key":"ref=5","first-page":"43","volume":"29","author":"Ravi V.","year":"2015","unstructured":"Ravi V.; Patel S.; Benjamin R.S.; Chemotherapy for soft-tissue sarcomas. Oncology  2015,29(1),43-50","journal-title":"Oncology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"Ye F.","year":"2023","unstructured":"Ye F.; Dewanjee S.; Li Y.; Jha N.K.; Chen Z-S.; Kumar A.; Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer  2023,22,105","journal-title":"Mol Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","volume":"27","author":"Ayodele O.","year":"2020","unstructured":"Ayodele O.; Razak A.R.A.; Immunotherapy in soft-tissue sarcoma. Curr Oncol  2020,27(11),17-23","journal-title":"Curr Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Peng Y.","year":"2022","unstructured":"Peng Y.; Wang Y.; Zhou C.; Mei W.; Zeng C.; PI3K\/Akt\/MTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol  2022,12,819128","journal-title":"Front Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.prmcm.2022.100136","volume":"4","author":"Mir T.G.","year":"2022","unstructured":"Mir T.G.; Wani A.K.; Singh J.; Shukla S.; Therapeutic application and toxicity associated with Crocus sativus (saffron) and its phytochemicals. Pharmacol. Res. -. Modern Chinese Med,  2022,4,100136","journal-title":"Modern Chinese Med,"},{"key":"ref=10","first-page":"122","volume":"12","author":"Wani A.K.","year":"2022","unstructured":"Wani A.K.; Akhtar N.; Sharma A.; El-Zahaby S.A.; fighting carcinogenesis with plant metabolites by weakening proliferative signaling and disabling replicative immortality networks of rapidly dividing and invading cancerous cells. Curr Drug Deliv  2022,12,122-139","journal-title":"Curr Drug Deliv"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9258396","volume":"2020","author":"Ortega M.A.","year":"2020","unstructured":"Ortega M.A.; Fraile-Mart\u00ednez O.; As\u00fansolo \u00c1.; Buj\u00e1n J.; Garc\u00eda-Honduvilla N.; Coca S.; Signal transduction pathways in breast cancer: The important role of PI3K\/Akt\/mTOR. J Oncol  2020,2020,1-11","journal-title":"J Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mc.20132","volume":"44","author":"Wilker E.","year":"2005","unstructured":"Wilker E.; Lu J.; Rho O.; Carbajal S.; Beltr\u00e1n L.; DiGiovanni J.; Role of PI3K\/Akt signaling in insulin\u2010like growth factor\u20101 (IGF\u20101) skin tumor promotion. Mol Carcinog  2005,44(2),137-145","journal-title":"Mol Carcinog"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"20152","DOI":"10.18632\/oncotarget.7918","volume":"7","author":"Song J.H.","year":"2016","unstructured":"Song J.H.; Padi S.K.R.; Luevano L.A.; Minden M.D.; DeAngelo D.J.; Hardiman G.; Ball L.E.; Warfel N.A.; Kraft A.S.; Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget  2016,7(15),20152-20165","journal-title":"Oncotarget"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/biom8010007","volume":"8","author":"Aziz A.","year":"2018","unstructured":"Aziz A.; Farid S.; Qin K.; Wang H.; Liu B.; PIM kinases and their relevance to the PI3K\/AKT\/mTOR pathway in the regulation of ovarian cancer. Biomolecules  2018,8(1),7","journal-title":"Biomolecules"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/ol.2022.13303","volume":"23","author":"Kyriazoglou A.","year":"2022","unstructured":"Kyriazoglou A.; Gkaralea L.; Kotsantis I.; Anastasiou M.; Pantazopoulos A.; Prevezanou M.; Chatzidakis I.; Kavourakis G.; Economopoulou P.; Nixon I.; Psyrri A.; Tyrosine kinase inhibitors in sarcoma treatment. Oncol Lett  [Review2022,23(6),183","journal-title":"Oncol Lett"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/ncb2763","volume":"15","author":"Dibble C.C.","year":"2013","unstructured":"Dibble C.C.; Manning B.D.; Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol  2013,15(6),555-564","journal-title":"Nat Cell Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/biom13020194","volume":"13","author":"Wani A.K.","year":"2023","unstructured":"Wani A.K.; Akhtar N.; Mir T.G.; Singh R.; Jha P.K.; Mallik S.K.; Sinha S.; Tripathi S.K.; Jain A.; Jha A.; Devkota H.P.; Prakash A.; Targeting apoptotic pathway of cancer cells with phytochemicals and plant-based nanomaterials. Biomolecules  2023,13(2),194","journal-title":"Biomolecules"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/genes11070719","volume":"11","author":"Fusco N.","year":"2020","unstructured":"Fusco N.; Sajjadi E.; Venetis K.; Gaudioso G.; Lopez G.; Corti C.; Guerini Rocco E.; Criscitiello C.; Malapelle U.; Invernizzi M.; PTEN alterations and their role in cancer management: Are we making headway on precision medicine? Genes  2020,11(7),719","journal-title":"Genes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/138920207782446160","volume":"8","author":"Arcaro A.","year":"2007","unstructured":"Arcaro A.; Guerreiro A.; The phosphoinositide 3-kinase pathway in human cancer: Genetic alterations and therapeutic implications. Curr Genomics  2007,8(5),271-306","journal-title":"Curr Genomics"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","volume":"111","author":"Perry J.A.","year":"2014","unstructured":"Perry J.A.; Kiezun A.; Tonzi P.; Van Allen E.M.; Carter S.L.; Baca S.C.; Cowley G.S.; Bhatt A.S.; Rheinbay E.; Pedamallu C.S.; Helman E.; Taylor-Weiner A.; McKenna A.; DeLuca D.S.; Lawrence M.S.; Ambrogio L.; Sougnez C.; Sivachenko A.; Walensky L.D.; Wagle N.; Mora J.; de Torres C.; Lavarino C.; Dos Santos Aguiar S.; Yunes J.A.; Brandalise S.R.; Mercado-Celis G.E.; Melendez-Zajgla J.; C\u00e1rdenas-Card\u00f3s R.; Velasco-Hidalgo L.; Roberts C.W.M.; Garraway L.A.; Rodriguez-Galindo C.; Gabriel S.B.; Lander E.S.; Golub T.R.; Orkin S.H.; Getz G.; Janeway K.A.; Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci  2014,111(51),E5564-E5573","journal-title":"Proc Natl Acad Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/cancers13061317","volume":"13","author":"Zaj\u0105c A.","year":"2021","unstructured":"Zaj\u0105c A.; Kr\u00f3l S.K.; Rutkowski P.; Czarnecka A.M.; Biological heterogeneity of chondrosarcoma: From (Epi) genetics through stemness and deregulated signaling to immunophenotype. Cancers  2021,13(6),1317","journal-title":"Cancers"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e93676","DOI":"10.1371\/journal.pone.0093676","volume":"9","author":"Jiang Y.","year":"2014","unstructured":"Jiang Y.; Subbiah V.; Janku F.; Ludwig J.A.; Naing A.; Benjamin R.S.; Brown R.E.; Anderson P.; Kurzrock R.; Novel secondary somatic mutations in Ewing\u2019s sarcoma and desmoplastic small round cell tumors. PLoS One  2014,9(8),e93676","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1126\/science.1150799","volume":"318","author":"Huang C.H.","year":"2007","unstructured":"Huang C.H.; Mandelker D.; Schmidt-Kittler O.; Samuels Y.; Velculescu V.E.; Kinzler K.W.; Vogelstein B.; Gabelli S.B.; Amzel L.M.; The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science  2007,318(5857),1744-1748","journal-title":"Science"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/1346-8138.16158","volume":"48","author":"Ren J.","year":"2021","unstructured":"Ren J.; Wang X.; Zhou Y.; Yue X.; Chen S.; Ding X.; Zeng S.; Jiang X.; Liu X.; Guo Q.; A novel SERPINE1\u2010FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K\u2010AKT\u2010mTOR signaling pathway and responsiveness to sirolimus. J Dermatol  2021,48(12),1900-1906","journal-title":"J Dermatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e26779","DOI":"10.1097\/MD.0000000000026779","volume":"100","author":"Wan H.","year":"2021","unstructured":"Wan H.; Zhang D.; Hu W.; Xie Z.; Du Q.; Xia Q.; Wen T.; Jia H.; Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma. Medicine  2021,100(30),e26779","journal-title":"Medicine"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41389-020-00300-z","volume":"10","author":"Yoon C.","year":"2021","unstructured":"Yoon C.; Lu J.; Yi B.C.; Chang K.K.; Simon M.C.; Ryeom S.; Yoon S.S.; PI3K\/Akt pathway and Nanog maintain cancer stem cells in sarcomas. Oncogenesis  2021,10(1),12","journal-title":"Oncogenesis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"113322","DOI":"10.1016\/j.yexcr.2022.113322","volume":"420","author":"Jin Z.","year":"2022","unstructured":"Jin Z.; Tao S.; Zhang C.; Xu D.; Zhu Z.; KIF20A promotes the development of fibrosarcoma via PI3K-Akt signaling pathway. Exp Cell Res  2022,420(1),113322","journal-title":"Exp Cell Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/sj.bjc.6605019","volume":"100","author":"Presneau N.","year":"2009","unstructured":"Presneau N.; Shalaby A.; Idowu B.; Gikas P.; Cannon S.R.; Gout I.; Diss T.; Tirabosco R.; Flanagan A.M.; Potential therapeutic targets for chordoma: PI3K\/AKT\/TSC1\/TSC2\/mTOR pathway. Br J Cancer  2009,100(9),1406-1414","journal-title":"Br J Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2045-3329-1-4","volume":"1","author":"Dewaele B.","year":"2011","unstructured":"Dewaele B.; Maggiani F.; Floris G.; Ampe M.; Vanspauwen V.; Wozniak A.; Debiec-Rychter M.; Sciot R.; Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res  2011,1(1),4","journal-title":"Clin Sarcoma Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/modpathol.3800435","volume":"18","author":"Schuetz A.N.","year":"2005","unstructured":"Schuetz A.N.; Rubin B.P.; Goldblum J.R.; Shehata B.; Weiss S.W.; Liu W.; Wick M.R.; Folpe A.L.; Intercellular junctions in Ewing sarcoma\/primitive neuroectodermal tumor: Additional evidence of epithelial differentiation. Mod Pathol  2005,18(11),1403-1410","journal-title":"Mod Pathol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1535-7163.MCT-18-0763","volume":"18","author":"Trautmann M.","year":"2019","unstructured":"Trautmann M.; Cyra M.; Isfort I.; Jeiler B.; Kr\u00fcger A.; Gr\u00fcnewald I.; Steinestel K.; Altvater B.; Rossig C.; Hafner S.; Simmet T.; Becker J.; \u00c5man P.; Wardelmann E.; Huss S.; Hartmann W.; Phosphatidylinositol-3-kinase (PI3K)\/Akt signaling is functionally essential in myxoid liposarcoma. Mol Cancer Ther  2019,18(4),834-844","journal-title":"Mol Cancer Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/1078-0432.CCR-16-2149","volume":"23","author":"Cuppens T.","year":"2017","unstructured":"Cuppens T.; Annibali D.; Coosemans A.; Trovik J.; ter Haar N.; Colas E.; Garcia-Jimenez A.; Van de Vijver K.; Kruitwagen R.P.M.; Brinkhuis M.; Zikan M.; Dundr P.; Huvila J.; Carp\u00e9n O.; Haybaeck J.; Moinfar F.; Salvesen H.B.; Stukan M.; Mestdagh C.; Zweemer R.P.; Massuger L.F.; Mallmann M.R.; Wardelmann E.; Mints M.; Verbist G.; Thomas D.; Gomm\u00e9 E.; Hermans E.; Moerman P.; Bosse T.; Amant F.; Potential targets\u2019 analysis reveals dual PI3K\/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas-an ENITEC Group initiative. Clin Cancer Res  2017,23(5),1274-1285","journal-title":"Clin Cancer Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/bjc.2014.471","volume":"112","author":"Zhu B.","year":"2015","unstructured":"Zhu B.; Davie J.K.; New insights into signalling-pathway alterations in rhabdomyosarcoma. Br J Cancer  2015,112(2),227-231","journal-title":"Br J Cancer"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1475-2867-13-36","volume":"13","author":"Kilic-Eren M.","year":"2013","unstructured":"Kilic-Eren M.; Boylu T.; Tabor V.; Targeting PI3K\/Akt represses hypoxia inducible factor-1\u03b1 activation and sensitizes rhabdomyosarcoma and ewing\u2019s sarcoma cells for apoptosis. Cancer Cell Int  2013,13(1),36","journal-title":"Cancer Cell Int"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/ijc.25829","volume":"129","author":"Friedrichs N.","year":"2011","unstructured":"Friedrichs N.; Trautmann M.; Endl E.; Sievers E.; Kindler D.; Wurst P.; Czerwitzki J.; Steiner S.; Renner M.; Penzel R.; Koch A.; Larsson O.; Tanaka S.; Kawai A.; Schirmacher P.; Mechtersheimer G.; Wardelmann E.; Buettner R.; Hartmann W.; Phosphatidylinositol\u20103\u2032\u2010kinase\/AKT signaling is essential in synovial sarcoma. Int J Cancer  2011,129(7),1564-1575","journal-title":"Int J Cancer"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00270-019-02259-w","volume":"42","author":"Bourcier K.","year":"2019","unstructured":"Bourcier K.; Le Cesne A.; Tselikas L.; Adam J.; Mir O.; Honore C.; de Baere T.; Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol  2019,42(9),1255-1261","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/BCTT.S134641","volume":"10","author":"Criscitiello C.","year":"2018","unstructured":"Criscitiello C.; viale, G.; Curigliano, G.; Goldhirsch, A. Profile of buparlisib and its potential in the treatment of breast cancer: Evidence to date. Breast Cancer  2018,10,23-29","journal-title":"Breast Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"114954","DOI":"10.1016\/j.ejmech.2022.114954","volume":"246","author":"Bhat A.A.","year":"2023","unstructured":"Bhat A.A.; Singh I.; Tandon N.; Tandon R.; Structure activity relationship (SAR) and anticancer activity of pyrrolidine derivatives: Recent developments and future prospects (A review). Eur J Med Chem  2023,246,114954","journal-title":"Eur J Med Chem"},{"key":"ref=39","first-page":"1","author":"Bhat A.A.","year":"2023","unstructured":"Bhat A.A.; Wani A.K.; Mir T.;  Introduction to ivermectin  2023,1-21","journal-title":"Introduction to ivermectin"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e30017","DOI":"10.1002\/pbc.30017","volume":"70","author":"Harrison D.","year":"2023","unstructured":"Harrison D.; Gill J.; Roth M.; Hingorani P.; Zhang W.; Teicher B.; Earley E.; Erickson S.; Gatto G.; Kurmasheva R.; Houghton P.; Smith M.; Anders Kolb E.; Gorlick R.; Evaluation of the pan\u2010class I phosphoinositide 3\u2010kinase (PI3K) inhibitor copanlisib in the pediatric preclinical testing consortium in vivo models of osteosarcoma. Pediatr Blood Cancer  2023,70(1),e30017","journal-title":"Pediatr Blood Cancer"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/PAS.0000000000000846","volume":"41","author":"Antonescu C.R.","year":"2017","unstructured":"Antonescu C.R.; Owosho A.A.; Zhang L.; Chen S.; Deniz K.; Huryn J.M.; Kao Y.C.; Huang S.C.; Singer S.; Tap W.; Schaefer I.M.; Fletcher C.D.; Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome. Am J Surg Pathol  2017,41(7),941-949","journal-title":"Am J Surg Pathol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/0008-5472.CAN-21-1222","volume":"82","author":"Carrabotta M.","year":"2022","unstructured":"Carrabotta M.; Laginestra M.A.; Durante G.; Mancarella C.; Landuzzi L.; Parra A.; Ruzzi F.; Toracchio L.; De Feo A.; Giusti V.; Pasello M.; Righi A.; Lollini P.L.; Palmerini E.; Donati D.M.; Manara M.C.; Scotlandi K.; Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma. Cancer Res  2022,82(4),708-720","journal-title":"Cancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2217\/fon-2022-0518","volume":"18","author":"Grignani G.","year":"2022","unstructured":"Grignani G.; Le Cesne A.; Mart\u00edn-Broto J.; Trabectedin as second-line treatment in advanced soft tissue sarcoma: Quality of life and safety outcomes. Future Oncol  2022,18(30s),13-22","journal-title":"Future Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","volume":"22","author":"Dolly S.O.","year":"2016","unstructured":"Dolly S.O.; Wagner A.J.; Bendell J.C.; Kindler H.L.; Krug L.M.; Seiwert T.Y.; Zauderer M.G.; Lolkema M.P.; Apt D.; Yeh R.F.; Fredrickson J.O.; Spoerke J.M.; Koeppen H.; Ware J.A.; Lauchle J.O.; Burris H.A.; de Bono J.S.; Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res  2016,22(12),2874-2884","journal-title":"Clin Cancer Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"a006140","DOI":"10.1101\/mcs.a006140","volume":"8","author":"Choo F.","year":"2022","unstructured":"Choo F.; Odintsov I.; Nusser K.; Nicholson K.S.; Davis L.; Corless C.L.; Stork L.; Somwar R.; Ladanyi M.; Davis J.L.; Davare M.A.; Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Molecular Case Studies  2022,8(1),a006140","journal-title":"Molecular Case Studies"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.3390\/molecules27092742","volume":"27","author":"Piazzi M.","year":"2022","unstructured":"Piazzi M.; Bavelloni A.; Cenni V.; Salucci S.; Bartoletti Stella A.; Tomassini E.; Scotlandi K.; Blalock W.L.; Faenza I.; Combined treatment with PI3K inhibitors BYL-719 and CAL-101 is a promising antiproliferative strategy in human rhabdomyosarcoma cells. Molecules  2022,27(9),2742","journal-title":"Molecules"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-22-0964","volume":"28","author":"Roeker L.E.","year":"2022","unstructured":"Roeker L.E.; Feldman T.A.; Soumerai J.D.; Falco V.; Panton G.; Dorsey C.; Zelenetz A.D.; Falchi L.; Park J.H.; Straus D.J.; Pena Velasquez C.; Lebowitz S.; Fox Y.; Battiato K.; Laudati C.; Thompson M.C.; McCarthy E.; Kdiry S.; Martignetti R.; Turpuseema T.; Purdom M.; Paskalis D.; Miskin H.P.; Sportelli P.; Leslie L.A.; Mato A.R.; Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach. Clin Cancer Res  2022,28(18),3958-3964","journal-title":"Clin Cancer Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","volume":"16","author":"Munoz J.","year":"2021","unstructured":"Munoz J.; Follows G.A.; Nastoupil L.J.; Copanlisib for the treatment of malignant lymphoma: Clinical experience and future perspectives. Target Oncol  2021,16(3),295-308","journal-title":"Target Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"Horwitz S.M.","year":"2018","unstructured":"Horwitz S.M.; Koch R.; Porcu P.; Oki Y.; Moskowitz A.; Perez M.; Myskowski P.; Officer A.; Jaffe J.D.; Morrow S.N.; Allen K.; Douglas M.; Stern H.; Sweeney J.; Kelly P.; Kelly V.; Aster J.C.; Weaver D.; Foss F.M.; Weinstock D.M.; Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood  2018,131(8),888-898","journal-title":"Blood"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"Markham A.","year":"2014","unstructured":"Markham A.; Idelalisib: First global approval. Drugs  2014,74(14),1701-1707","journal-title":"Drugs"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2174\/1574893616666210707101516","volume":"25","author":"Liu M.","year":"2022","unstructured":"Liu M.; Zhang W.E.; Xing K.; Zhou P.; Li J.; Inhibitory effect of PD-1\/PD-L1 and blockade immunotherapy in leukemia. Comb Chem High Throughput Screen  2022,25(9),1399-1410","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e0133610","DOI":"10.1371\/journal.pone.0133610","volume":"10","author":"Anderson J.L.","year":"2015","unstructured":"Anderson J.L.; Park A.; Akiyama R.; Tap W.D.; Denny C.T.; Federman N.; Evaluation of in vitro activity of the class I PI3K inhibitor buparlisib (BKM120) in pediatric bone and soft tissue sarcomas. PLoS One  2015,10(9),e0133610","journal-title":"PLoS One"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1158\/1535-7163.MCT-09-0160","volume":"8","author":"Liu T-J.","year":"2009","unstructured":"Liu T-J.; Koul D.; LaFortune T.; Tiao N.; Shen R.J.; Maira S-M.; Garcia-Echevrria C.; Alfred Yung W.K.; NVP-BEZ235, A novel dual PI3K\/MTOR inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther  2009,8,2204-2210","journal-title":"Mol Cancer Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"018546","DOI":"10.1182\/blood.2022018546","volume":"2022","author":"Rao V.K.","year":"2022","unstructured":"Rao V.K.; Webster S.; \u0160ediv\u00e1 A.; Plebani A.; Schuetz C.; Shcherbina A.; Conlon N.; Coulter T.I.; Dalm V.A.; Trizzino A.; Randomized, placebo-controlled, phase 3 trial of PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood  2022,2022,018546","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/cas.15308","volume":"113","author":"Fukuhara N.","year":"2022","unstructured":"Fukuhara N.; Suehiro Y.; Kato H.; Kusumoto S.; Coronado C.; Rappold E.; Zhao W.; Li J.; Gilmartin A.; Izutsu K.; Parsaclisib in Japanese patients with relapsed or refractory B\u2010cell lymphoma (CITADEL\u2010111): A phase Ib study. Cancer Sci  2022,113(5),1702-1711","journal-title":"Cancer Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","volume":"65","author":"Hanan E.J.","year":"2022","unstructured":"Hanan E.J.; Braun M.G.; Heald R.A.; MacLeod C.; Chan C.; Clausen S.; Edgar K.A.; Eigenbrot C.; Elliott R.; Endres N.; Friedman L.S.; Gogol E.; Gu X.H.; Thibodeau R.H.; Jackson P.S.; Kiefer J.R.; Knight J.D.; Nannini M.; Narukulla R.; Pace A.; Pang J.; Purkey H.E.; Salphati L.; Sampath D.; Schmidt S.; Sideris S.; Song K.; Sujatha-Bhaskar S.; Ultsch M.; Wallweber H.; Xin J.; Yeap S.; Young A.; Zhong Y.; Staben S.T.; Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1. J Med Chem  2022,65(24),16589-16621","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s12185-022-03450-5","volume":"116","author":"Goto H.","year":"2022","unstructured":"Goto H.; Izutsu K.; Ennishi D.; Mishima Y.; Makita S.; Kato K.; Hanaya M.; Hirano S.; Narushima K.; Teshima T.; Nagai H.; Ishizawa K.; Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin\u2019s lymphoma: An open-label, multicenter, dose-escalation phase 1 study. Int J Hematol  2022,116(6),911-921","journal-title":"Int J Hematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"11511","DOI":"10.3390\/ijms222111511","volume":"22","author":"Omeljaniuk W.J.","year":"2021","unstructured":"Omeljaniuk W.J.; Kr\u0119towski R.; Ratajczak-Wrona W.; Jab\u0142o\u0144ska E.; Cechowska-Pasko M.; Novel dual PI3K\/mTOR inhibitor, apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells. Int J Mol Sci  2021,22(21),11511","journal-title":"Int J Mol Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.3390\/cells10112916","volume":"10","author":"Hsin I.L.","year":"2021","unstructured":"Hsin I.L.; Shen H.P.; Chang H.Y.; Ko J.L.; Wang P.H.; Suppression of PI3K\/Akt\/mTOR\/c-Myc\/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K\/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells  2021,10(11),2916","journal-title":"Cells"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41598-021-04265-w","volume":"12","author":"Xu Y.","year":"2022","unstructured":"Xu Y.; Afify S.M.; Du J.; Liu B.; Hassan G.; Wang Q.; Li H.; Liu Y.; Fu X.; Zhu Z.; Chen L.; Seno M.; The efficacy of PI3K\u03b3 and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Sci Rep  2022,12(1),347","journal-title":"Sci Rep"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12935-021-01800-7","volume":"21","author":"Liu C.","year":"2021","unstructured":"Liu C.; Xing W.; Yu H.; Zhang W.; Si T.; ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells. Cancer Cell Int  2021,21(1),108","journal-title":"Cancer Cell Int"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"615146","DOI":"10.3389\/fonc.2020.615146","volume":"10","author":"Liang C.","year":"2021","unstructured":"Liang C.; Yu X.; Xiong N.; Zhang Z.; Sun Z.; Dong Y.; Pictilisib enhances the antitumor effect of doxorubicin and prevents tumor-mediated bone destruction by blockade of PI3K\/AKT pathway. Front Oncol  2021,10,615146","journal-title":"Front Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e927106","DOI":"10.12659\/MSM.927106","volume":"26","author":"Zhu D.","year":"2020","unstructured":"Zhu D.; Dong J.; Xu Y.; Zhang X.; Fu S.; Liu W.; Omipalisib inhibits esophageal squamous cell carcinoma growth through inactivation of phosphoinositide 3-kinase (PI3K)\/AKT\/Mammalian Target of Rapamycin (mTOR) and ERK signaling. Med Sci Monit  2020,26,e927106","journal-title":"Med Sci Monit"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1166\/jbn.2022.3279","volume":"18","author":"Zhou S.","year":"2022","unstructured":"Zhou S.; Ma Y.; Xu R.; Tang X.; Nanoparticles loaded with gsk1059615 combined with sorafenib inhibited programmed cell death 1 ligand 1 expression by negatively regulating the PI3K\/Akt\/NF- \u03ba B Pathway, thereby reversing the drug resistance of hepatocellular carcinoma to sorafenib. J Biomed Nanotechnol  2022,18(3),693-704","journal-title":"J Biomed Nanotechnol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-018-0055-x","volume":"8","author":"Kater A.P.","year":"2018","unstructured":"Kater A.P.; Tonino S.H.; Spiering M.; Chamuleau M.E.D.; Liu R.; Adewoye A.H.; Gao J.; Dreiling L.; Xin Y.; Doorduijn J.K.; Kersten M.J.; Final results of a phase 1b study of the safety and efficacy of the PI3K\u03b4 inhibitor acalisib (GS-9820) in relapsed\/refractory lymphoid malignancies. Blood Cancer J  2018,8(2),16","journal-title":"Blood Cancer J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"692053","DOI":"10.3389\/fonc.2021.692053","volume":"11","author":"Ceccarelli M.","year":"2021","unstructured":"Ceccarelli M.; D\u2019Andrea G.; Micheli L.; Gentile G.; Cavallaro S.; Merlino G.; Papoff G.; Tirone F.; Tumor growth in the high frequency medulloblastoma mouse model Ptch1+\/\u2212\/Tis21KO has a specific activation signature of the PI3K\/AKT\/mTOR pathway and is counteracted by the pi3k inhibitor MEN1611. Front Oncol  2021,11,692053","journal-title":"Front Oncol"},{"key":"ref=67","first-page":"300","author":"Akhtar N.","year":"2021","unstructured":"Akhtar N.; Wani A.K.; Mir T-U.G.; Kumar N.; Mannan M.A-U.; Sapindus mukorossi: Ethnomedicinal uses, phytochemistry, and pharmacological activities. Plant Cell Biotechnol Mol Biol  2021,300-319","journal-title":"Plant Cell Biotechnol Mol Biol"},{"key":"ref=68","first-page":"100702","author":"Selwal N.","year":"2023","unstructured":"Selwal N.; Rahayu F.; Herwati A.; Latifah E.; Suhara C.; Suastika I.B.K.; Mahayu W.M.; Wani A.K.; Enhancing secondary metabolite production in plants: Exploring traditional and modern strategies. J Agric Food Res  2023,100702","journal-title":"J Agric Food Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms232213689","author":"Jang J.Y.","year":"2022","unstructured":"Jang J.Y.; Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: A review. Int J Mol Sci  2022,23","journal-title":"Int J Mol Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2174\/18715206113139990119","volume":"13","author":"Tong X.","year":"2013","unstructured":"Tong X.; Pelling J.; Targeting the PI3K\/Akt\/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem  2013,13(7),971-978","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jtumed.2017.05.012","volume":"12","author":"Kiptiyah K.","year":"2017","unstructured":"Kiptiyah K.; Widodo W.; Ciptadi G.; Aulanni\u2019am A.; Widodo M.A.; Sumitro S.B.; 10-Gingerol as an inducer of apoptosis through HTR1A in cumulus cells: In-vitro and in-silico studies. J Taibah Univ Med Sci  2017,12(5),397-406","journal-title":"J Taibah Univ Med Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1038\/s41598-020-62136-2","volume":"10","author":"Chen B.H.","year":"2020","unstructured":"Chen B.H.; Hsieh C.H.; Tsai S.Y.; Wang C.Y.; Wang C.C.; Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci Rep  2020,10(1),5163","journal-title":"Sci Rep"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/biom9070270","volume":"9","author":"Paulraj F.","year":"2019","unstructured":"Paulraj F.; Abas F.H.; Lajis N.; Othman I.; Naidu R.; Molecular pathways modulated by curcumin analogue, diarylpentanoids in cancer. Biomolecules  2019,9(7),270","journal-title":"Biomolecules"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"174954","DOI":"10.1016\/j.ejphar.2022.174954","volume":"927","author":"Gan L.","year":"2022","unstructured":"Gan L.; Leng Y.; Min J.; Luo X.M.; Wang F.; Zhao J.; Kaempferol promotes the osteogenesis in rBMSCs via mediation of SOX2\/miR-124-3p\/PI3K\/Akt\/mTOR axis. Eur J Pharmacol  2022,927,174954","journal-title":"Eur J Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.17219\/acem\/161165","volume":"32","author":"Lewandowski D.","year":"2023","unstructured":"Lewandowski D.; Szewczyk A.; Radzka J.; Dubi\u0144ska-Magiera M.; Kazimierczak W.; Daczewska M.; Migocka-Patrza\u0142ek M.; The natural origins of cytostatic compounds used in rhabdomyosarcoma therapy. Adv Clin Exp Med  2023,32(10),1179-1191","journal-title":"Adv Clin Exp Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1055\/s-0042-1755401","volume":"2","author":"Zhai Y.","year":"2022","unstructured":"Zhai Y.; Jiang S.; Li B.; Miao L.; Wang J.; Li S.; Potential mechanisms of yanghe decoction in the treatment of soft tissue sarcoma and arteriosclerosis obliterans based on network pharmacology. Chinese Med Nat Prod  2022,2(2),e77-e88","journal-title":"Chinese Med Nat Prod"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/2211-5463.13391","volume":"12","author":"Khiewkamrop P.","year":"2022","unstructured":"Khiewkamrop P.; Surangkul D.; Srikummool M.; Richert L.; Pekthong D.; Parhira S.; Somran J.; Srisawang P.; Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells. FEBS Open Bio  2022,12(5),937-958","journal-title":"FEBS Open Bio"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s10147-012-0387-7","volume":"18","author":"Kondo A.","year":"2013","unstructured":"Kondo A.; Takeda T.; Li B.; Tsuiji K.; Kitamura M.; Wong T.F.; Yaegashi N.; Epigallocatechin-3-gallate potentiates curcumin\u2019s ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis. Int J Clin Oncol  2013,18(3),380-388","journal-title":"Int J Clin Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jad.2022.08.026","volume":"316","author":"Guo L.","year":"2022","unstructured":"Guo L.; Qu B.; Song C.; Zhu S.; Gong N.; Sun J.; Celastrol attenuates 6-hydroxydopamine-induced neurotoxicity by regulating the miR-146a\/PI3K\/Akt\/mTOR signaling pathways in differentiated rat pheochromocytoma cells. J Affect Disord  2022,316,233-242","journal-title":"J Affect Disord"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9911537","volume":"2021","author":"Farhan M.","year":"2021","unstructured":"Farhan M.; Silva M.; Xingan X.; Zhou Z.; Zheng W.; Artemisinin inhibits the migration and invasion in uveal melanoma via inhibition of the PI3K\/AKT\/mTOR signaling pathway. Oxid Med Cell Longev  2021,2021,1-16","journal-title":"Oxid Med Cell Longev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.3892\/ol.2018.8909","volume":"16","author":"Wang Z.","year":"2018","unstructured":"Wang Z.; Li Y.; Zhou F.; Piao Z.; Hao J.; \u03b2 elemene enhances anticancer bone neoplasms efficacy of paclitaxel through regulation of GPR124 in bone neoplasms cells. Oncol Lett  2018,16(2),2143-2150","journal-title":"Oncol Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/molecules21050529","volume":"21","author":"Chan W.K.","year":"2016","unstructured":"Chan W.K.; Tan L.; Chan K.G.; Lee L.H.; Goh B.H.; Nerolidol: A sesquiterpene alcohol with multi-faceted pharmacological and biological activities. Molecules  2016,21(5),529","journal-title":"Molecules"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/tox.23522","volume":"37","author":"Yu Y.","year":"2022","unstructured":"Yu Y.; Velu P.; Ma Y.; Vijayalakshmi A.; Nerolidol induced apoptosis via PI3K\/JNK regulation through cell cycle arrest in MG \u201063 osteosarcoma cells. Environ Toxicol  2022,37(7),1750-1758","journal-title":"Environ Toxicol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"113092","DOI":"10.1016\/j.ejmech.2020.113092","volume":"210","author":"Fang Y.","year":"2021","unstructured":"Fang Y.; Li H.; Ji B.; Cheng K.; Wu B.; Li Z.; Zheng C.; Hua H.; Li D.; Renieramycin-type alkaloids from marine-derived organisms: Synthetic chemistry, biological activity and structural modification. Eur J Med Chem  2021,210,113092","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.biopha.2017.09.066","volume":"97","author":"Chen S.","year":"2018","unstructured":"Chen S.; Jin Z.; Dai L.; Wu H.; Wang J.; Wang L.; Zhou Z.; Yang L.; Gao W.; Aloperine induces apoptosis and inhibits invasion in MG-63 and U2OS human osteosarcoma cells. Biomed Pharmacother  2018,97,45-52","journal-title":"Biomed Pharmacother"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09168451.2019.1659714","volume":"84","author":"Shinji S.","year":"2020","unstructured":"Shinji S.; Nakamura S.; Nihashi Y.; Umezawa K.; Takaya T.; Berberine and palmatine inhibit the growth of human rhabdomyosarcoma cells. Biosci Biotechnol Biochem  2020,84(1),63-75","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.pharmthera.2012.10.004","volume":"137","author":"Grohar P.J.","year":"2013","unstructured":"Grohar P.J.; Helman L.J.; Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther  2013,137(2),216-224","journal-title":"Pharmacol Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"104775","DOI":"10.1016\/j.tiv.2020.104775","volume":"65","author":"Zhou J.","year":"2020","unstructured":"Zhou J.; Huang Z.; Ni X.; Lv C.; Piperlongumine induces apoptosis and G2\/M phase arrest in human osteosarcoma cells by regulating ROS\/PI3K\/Akt pathway. Toxicol In Vitro  2020,65,104775","journal-title":"Toxicol In Vitro"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s13277-013-1223-z","volume":"35","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Sun S.; Chen J.; Ren P.; Hu Y.; Cao Z.; Sun H.; Ding Y.; Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG\/HOS cells through inhibition of PI3K\/Akt pathway. Tumour Biol  2014,35(2),1619-1625","journal-title":"Tumour Biol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ijmm.2017.3013","volume":"40","author":"Li X.","year":"2017","unstructured":"Li X.; Yang Z.; Han W.; Lu X.; Jin S.; Yang W.; Li J.; He W.; Qian Y.; Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways. Int J Mol Med  2017,40(2),311-318","journal-title":"Int J Mol Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e2000639","DOI":"10.1002\/cbdv.202000639","volume":"18","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Li M.; Zhang Q.; Wang Z.; Li X.; Bao J.; Zhang H.; Arthpyrone L, a new pyridone alkaloid from a deep\u2010sea arthrinium sp., inhibits proliferation of MG63 osteosarcoma cells by inducing G0\/G1 arrest and apoptosis. Chem Biodivers  2021,18(2),e2000639","journal-title":"Chem Biodivers"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.3390\/nu14112187","volume":"14","author":"Frasinariu O.","year":"2022","unstructured":"Frasinariu O.; Serban R.; Trandafir L.M.; Miron I.; Starcea M.; Vasiliu I.; Alisi A.; Temneanu O.R.; The role of phytosterols in nonalcoholic fatty liver disease. Nutrients  2022,14(11),2187","journal-title":"Nutrients"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1055\/a-1176-1884","volume":"86","author":"Han B.","year":"2020","unstructured":"Han B.; Jiang L.; Jiang P.; Zhou D.; Jia X.; Li X.; Ye X.; Daucosterol linolenate from sweet potato suppresses MCF7-Xenograft-tumor growth through regulating PI3K\/AKT pathway. Planta Med  2020,86(11),767-775","journal-title":"Planta Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11011-020-00575-6","volume":"35","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Song Y.; Feng C.; Improvement of cerebral ischemia\/reperfusion injury by daucosterol palmitate-induced neuronal apoptosis inhibition via PI3K\/Akt\/mTOR signaling pathway. Metab Brain Dis  2020,35(6),1035-1044","journal-title":"Metab Brain Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.intimp.2007.03.010","volume":"7","author":"Moon D.O.","year":"2007","unstructured":"Moon D.O.; Lee K.J.; Choi Y.H.; Kim G.Y.; \u03b2-Sitosterol-induced-apoptosis is mediated by the activation of ERK and the downregulation of Akt in MCA-102 murine fibrosarcoma cells. Int Immunopharmacol  2007,7(8),1044-1053","journal-title":"Int Immunopharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3892\/ijo.2011.1051","volume":"39","author":"Tsuchiya H.","year":"2011","unstructured":"Tsuchiya H.; Sugimoto N.; Shirai T.; Hayashi K.; Nishida H.; Ohnari I.; Takeuchi A.; Yachie A.; Tsuchiya H.; Caffeine activates tumor suppressor PTEN in sarcoma cells. Int J Oncol  2011,39(2),465-472","journal-title":"Int J Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3727\/096504015X14298122915583","volume":"22","author":"Eo S.H.","year":"2015","unstructured":"Eo S.H.; Kim J.H.; Kim S.J.; Induction of G 2\/M arrest by berberine via activation of PI3K\/Akt and p38 in human chondrosarcoma cell line. Oncol Res  2015,22(3),147-157","journal-title":"Oncol Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ijc.25134","volume":"127","author":"Chetty C.","year":"2010","unstructured":"Chetty C.; Lakka S.S.; Bhoopathi P.; Rao J.S.; MMP\u20102 alters VEGF expression via \u03b1V\u03b23 integrin\u2010mediated PI3K\/AKT signaling in A549 lung cancer cells. Int J Cancer  2010,127(5),1081-1095","journal-title":"Int J Cancer"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000490151","volume":"63","author":"Chen J.","year":"2018","unstructured":"Chen J.; Liu C.; Yang Q.Q.; Ma R.B.; Ke Y.; Dong F.; Wu X.E.; Isoliquiritigenin suppresses osteosarcoma U2OS cell proliferation and invasion by regulating the PI3K\/Akt signalling pathway. Chemotherapy  2018,63(3),155-161","journal-title":"Chemotherapy"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.yexmp.2019.04.005","volume":"108","author":"Gao K.","year":"2019","unstructured":"Gao K.; Su Z.; Liu H.; Liu Y.; RETRACTED: Anti-proliferation and anti-metastatic effects of sevoflurane on human osteosarcoma U2OS and Saos-2 cells. Exp Mol Pathol  2019,108,121-130","journal-title":"Exp Mol Pathol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"109275","DOI":"10.1016\/j.cbi.2020.109275","volume":"331","author":"Ma K.","year":"2020","unstructured":"Ma K.; Zhang C.; Li W.; Gamabufotalin suppressed osteosarcoma stem cells through the TGF-\u03b2\/periostin\/PI3K\/AKT pathway. Chem Biol Interact  2020,331,109275","journal-title":"Chem Biol Interact"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3892\/or.2015.4084","volume":"34","author":"Meng Z.J.","year":"2015","unstructured":"Meng Z.J.; Wu N.; Liu Y.; Shu K.J.; Zou X.; Zhang R.X.; Pi C.J.; He B.C.; Ke Z.Y.; Chen L.; Deng Z.L.; Yin L.J.; Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K\/Akt signaling. Oncol Rep  2015,34(3),1388-1396","journal-title":"Oncol Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3892\/ijmm.2018.3433","volume":"41","author":"Yang J.","year":"2018","unstructured":"Yang J.; Zou Y.; Jiang D.; Honokiol suppresses proliferation and induces apoptosis via regulation of the miR 21\/PTEN\/PI3K\/AKT signaling pathway in human osteosarcoma cells. Int J Mol Med  2018,41(4),1845-1854","journal-title":"Int J Mol Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/jf200620n","volume":"59","author":"Krajarng A.","year":"2011","unstructured":"Krajarng A.; Nakamura Y.; Suksamrarn S.; Watanapokasin R.; \u03b1-Mangostin induces apoptosis in human chondrosarcoma cells through downregulation of ERK\/JNK and Akt signaling pathway. J Agric Food Chem  2011,59(10),5746-5754","journal-title":"J Agric Food Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.3892\/mmr.2020.11484","volume":"22","author":"Zheng M.","year":"2020","unstructured":"Zheng M.; Wu Y.; Piceatannol suppresses proliferation and induces apoptosis by regulation of the microRNA 21\/phosphatase and tensin homolog\/protein kinase B signaling pathway in osteosarcoma cells. Mol Med Rep  2020,22(5),3985-3993","journal-title":"Mol Med Rep"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/mnfr.201000292","volume":"55","author":"Hwang Y.P.","year":"2011","unstructured":"Hwang Y.P.; Yun H.J.; Choi J.H.; Han E.H.; Kim H.G.; Song G.Y.; Kwon K.; Jeong T.C.; Jeong H.G.; Suppression of EGF\u2010induced tumor cell migration and matrix metalloproteinase\u20109 expression by capsaicin via the inhibition of EGFR\u2010mediated FAK\/Akt, PKC\/Raf\/ERK, p38 MAPK, and AP\u20101 signaling. Mol Nutr Food Res  2011,55(4),594-605","journal-title":"Mol Nutr Food Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.bbrc.2005.08.247","volume":"336","author":"Miyata Y.","year":"2005","unstructured":"Miyata Y.; Sato T.; Ito A.; Triptolide, a diterpenoid triepoxide, induces antitumor proliferation via activation of c-Jun NH2-terminal kinase 1 by decreasing phosphatidylinositol 3-kinase activity in human tumor cells. Biochem Biophys Res Commun  2005,336(4),1081-1086","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.2147\/DDDT.S277160","volume":"14","author":"Huang Y.","year":"2020","unstructured":"Huang Y.; Chen J.; Yang S.; Tan T.; Wang N.; Wang Y.; Zhang L.; Yang C.; Huang H.; Luo J.; Luo X.; Cinnamaldehyde inhibits the function of osteosarcoma by suppressing the Wnt\/\u03b2-Catenin and PI3K\/Akt signaling pathways. Drug Des Devel Ther  2020,14,4625-4637","journal-title":"Drug Des Devel Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/or.2022.8261","volume":"47","author":"Wang Y.","year":"2022","unstructured":"Wang Y.; Chen J.; Huang Y.; Yang S.; Tan T.; Wang N.; Zhang J.; Ye C.; Wei M.; Luo J.; Luo X.; Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt\/\u03b2 catenin and PI3K\/Akt signaling pathways. Oncol Rep  2022,47(3),50","journal-title":"Oncol Rep"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3892\/ijo.2016.3701","volume":"49","author":"Zhang R.X.","year":"2016","unstructured":"Zhang R.X.; Li Y.; Tian D.D.; Liu Y.; Nian W.; Zou X.; Chen Q.Z.; Zhou L.Y.; Deng Z.L.; He B.C.; Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt\/\u03b2-catenin signaling in human osteosarcoma cells. Int J Oncol  2016,49(5),1973-1982","journal-title":"Int J Oncol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41419-018-0684-9","volume":"9","author":"Zhu J.","year":"2018","unstructured":"Zhu J.; Sun Y.; Lu Y.; Jiang X.; Ma B.; Yu L.; Zhang J.; Dong X.; Zhang Q.; Glaucocalyxin A.; Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K\/Akt pathway. Cell Death Dis  2018,9(6),708","journal-title":"Cell Death Dis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3892\/or.2014.3192","volume":"32","author":"Gweon E.J.","year":"2014","unstructured":"Gweon E.J.; Kim S.J.; Resveratrol attenuates matrix metalloproteinase-9 and -2- regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep  2014,32(1),71-78","journal-title":"Oncol Rep"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3892\/mmr.2019.10882","volume":"21","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Weng Q.; Han J.; Chen J.; Alantolactone suppresses human osteosarcoma through the PI3K\/AKT signaling pathway. Mol Med Rep  2019,21(2),675-684","journal-title":"Mol Med Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"110068","DOI":"10.1016\/j.cbi.2022.110068","volume":"365","author":"Huang H.","year":"2022","unstructured":"Huang H.; Lu Q.; Yuan X.; Zhang P.; Ye C.; Wei M.; Yang C.; Zhang L.; Huang Y.; Luo X.; Luo J.; Andrographolide inhibits the growth of human osteosarcoma cells by suppressing Wnt\/\u03b2-catenin, PI3K\/AKT and NF-\u03baB signaling pathways. Chem Biol Interact  2022,365,110068","journal-title":"Chem Biol Interact"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5040326","volume":"2021","author":"Liu M.Y.","year":"2021","unstructured":"Liu M.Y.; Liu F.; Li Y.J.; Yin J.N.; Gao Y.L.; Wang X.Y.; Yang C.; Liu J.G.; Li H.J.; Ginsenoside Rg5 inhibits human osteosarcoma cell proliferation and induces cell apoptosis through PI3K\/Akt\/mTORC1-Related LC3 autophagy pathway. Oxid Med Cell Longev  2021,2021,1-12","journal-title":"Oxid Med Cell Longev"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1016\/j.sjbs.2021.05.006","volume":"28","author":"Mickymaray S.","year":"2021","unstructured":"Mickymaray S.; Alfaiz F.A.; Paramasivam A.; Veeraraghavan V.P.; Periadurai N.D.; Surapaneni K.M.; Niu G.; Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway. Saudi J Biol Sci  2021,28(7),3641-3649","journal-title":"Saudi J Biol Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"25","DOI":"10.36686\/Ariviyal.CSER.2021.03.06.031","volume":"3","author":"Bhat A.A.","year":"2021","unstructured":"Bhat A.A.; Thoker B.A.; Wani A.K.; Sheergojri G.A.; Kaloo M.A.; Bhat B.A.; Ahmad Rizvi S.M.; Rizvi M.; Synthesis and characterization of copper oxide nanoparticles by coprecipitation method: Electronic and antimicrobial properties. Chem Sci Eng Res  2021,3(6),25-29","journal-title":"Chem Sci Eng Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33805\/2690-2575.109","volume":"1\u20135","author":"Bilal Ahmad T.","year":"2020","unstructured":"Bilal Ahmad T.; Asif A.B.; Atif Khurshid; Masood, A.K.; Gulzar Ahmad, S. Preparation and characterization of SnO2 nanoparticles for antibacterial properties. Nanomat Chem Technol  2020,1\u20135,1-5","journal-title":"Nanomat Chem Technol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"13107","DOI":"10.1039\/c1jm11401h","volume":"21","author":"Xue X.","year":"2011","unstructured":"Xue X.; Wang F.; Liu X.; Emerging functional nanomaterials for therapeutics. J Mater Chem  2011,21(35),13107-13127","journal-title":"J Mater Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.rvsc.2017.11.018","volume":"117","author":"Benton J.Z.","year":"2018","unstructured":"Benton J.Z.; Williams R.J.; Patel A.; Meichner K.; Tarigo J.; Nagata K.; Pethel T.D.; Gogal R.M.; Gold nanoparticles enhance radiation sensitization and suppress colony formation in a feline injection site sarcoma cell line, in vitro. Res Vet Sci  2018,117,104-110","journal-title":"Res Vet Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1021\/acs.bioconjchem.7b00774","volume":"29","author":"Naumann J.A.","year":"2018","unstructured":"Naumann J.A.; Widen J.C.; Jonart L.A.; Ebadi M.; Tang J.; Gordon D.J.; Harki D.A.; Gordon P.M.; SN-38 conjugated gold nanoparticles activated by ewing sarcoma specific mRNAs exhibit in vitro and in vivo efficacy. Bioconjug Chem  2018,29(4),1111-1118","journal-title":"Bioconjug Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/cmi.2015.05","volume":"13","author":"Chakraborty B.","year":"2016","unstructured":"Chakraborty B.; Pal R.; Ali M.; Singh L.M.; Shahidur Rahman D.; Kumar Ghosh S.; Sengupta M.; Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma. Cell Mol Immunol  2016,13(2),191-205","journal-title":"Cell Mol Immunol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"101364","DOI":"10.1016\/j.tranon.2022.101364","volume":"18","author":"Sanaei M.J.","year":"2022","unstructured":"Sanaei M.J.; Razi S.; Pourbagheri-Sigaroodi A.; Bashash D.; The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles. Transl Oncol  2022,18,101364","journal-title":"Transl Oncol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2202337","DOI":"10.1002\/smll.202202337","volume":"18","author":"Fu Y.","year":"2022","unstructured":"Fu Y.; He G.; Liu Z.; Wang J.; Li M.; Zhang Z.; Bao Q.; Wen J.; Zhu X.; Zhang C.; Zhang W.; DNA base pairing\u2010inspired supramolecular nanodrug camouflaged by cancer\u2010cell membrane for osteosarcoma treatment. Small  2022,18(30),2202337","journal-title":"Small"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.xphs.2018.01.006","volume":"107","author":"Demirbolat G.M.","year":"2018","unstructured":"Demirbolat G.M.; Altintas L.; Yilmaz S.; Degim I.T.; Development of orally applicable, combinatorial drug-loaded nanoparticles for the treatment of fibrosarcoma. J Pharm Sci  2018,107(5),1398-1407","journal-title":"J Pharm Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-022-09176-1","volume":"22","author":"Tian Z.","year":"2022","unstructured":"Tian Z.; Dong S.; Yang Y.; Gao S.; Yang Y.; Yang J.; Zhang P.; Wang X.; Yao W.; Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study. BMC Cancer  2022,22(1),56","journal-title":"BMC Cancer"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1158\/1078-0432.CCR-19-2597","volume":"26","author":"Dodd R.D.","year":"2020","unstructured":"Dodd R.D.; Scherer A.; Huang W.; McGivney G.R.; Gutierrez W.R.; Laverty E.A.; Ashcraft K.A.; Stephens V.R.; Yousefpour P.; Saha S.; Knepper-Adrian V.; Floyd W.; Chen M.; Ma Y.; Mastria E.M.; Cardona D.M.; Eward W.C.; Chilkoti A.; Kirsch D.G.; Tumor subtype determines therapeutic response to chimeric polypeptide nanoparticle-based chemotherapy in Pten -deleted mouse models of sarcoma. Clin Cancer Res  2020,26(18),5036-5047","journal-title":"Clin Cancer Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00203-022-02757-5","volume":"204","author":"Wani A.K.","year":"2022","unstructured":"Wani A.K.; Akhtar N.; Sher F.; Navarrete A.A.; Am\u00e9rico-Pinheiro J.H.P.; Microbial adaptation to different environmental conditions: Molecular perspective of evolved genetic and cellular systems. Arch Microbiol  2022,204(2),144","journal-title":"Arch Microbiol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.bcab.2023.102829","volume":"52","author":"Wani A.K.","year":"2023","unstructured":"Wani A.K.; Chopra C.; Singh R.; Ahmad S.; Am\u00e9rico-Pinheiro J.H.P.; Mining microbial tapestry using high-throughput sequencing and in silico analysis of Trehalose synthase (TreS) derived from hot spring metagenome. Biocatal Agric Biotechnol  2023,52,102829","journal-title":"Biocatal Agric Biotechnol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"119","DOI":"10.7324\/JABB.2023.11514-1","volume":"11","author":"Dhanjal D.S.","year":"2023","unstructured":"Dhanjal D.S.; Singh S.; Kumar V.; Ramamurthy P.C.; Chopra C.; Wani A.K.; Singh R.; Singh J.; Isolation and characterization of cellulase-producing myxobacterial strain from the unique niche of mirgund wetland from the north-western himalayas. J Appl Biol Biotechnol  2023,11,119-125","journal-title":"J Appl Biol Biotechnol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-824523-1.00003-1","author":"Wani A.K.","year":"2021","unstructured":"Wani A.K.; Akhtar N.; Datta B.; Pandey J.; Mannan M.A.;  Volatiles and metabolites of microbes  2021,283-303","journal-title":"Volatiles and metabolites of microbes"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"135175","DOI":"10.1016\/j.molstruc.2023.135175","volume":"1283","author":"Bhat A.A.","year":"2023","unstructured":"Bhat A.A.; Tandon N.; Singh I.; Tandon R.; Structure-activity relationship (SAR) and antibacterial activity of pyrrolidine based hybrids: A review. J Mol Struct  2023,1283,135175","journal-title":"J Mol Struct"},{"key":"ref=133","author":"Diwan D.","year":"2021","unstructured":"Diwan D.; Cheng L.; Usmani Z.; Sharma M.; Holden N.; Willoughby N.; Sangwan N.; Baadhe R.R.; Liu C.; Gupta V.K.;  Microbial Cancer Therapeutics: A Promising Approach  2021","journal-title":"Microbial Cancer Therapeutics: A Promising Approach"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fphar.2017.00828","volume":"8","author":"Agrawal S.","year":"2017","unstructured":"Agrawal S.; Acharya D.; Adholeya A.; Barrow C.J.; Deshmukh S.K.; Nonribosomal peptides from marine microbes and their antimicrobial and anticancer potential. Front Pharmacol  2017,8,828","journal-title":"Front Pharmacol"},{"key":"ref=135","first-page":"131","volume":"10","author":"Franco Y.L.","year":"2018","unstructured":"Franco Y.L.; Vaidya T.R.; Ait-Oudhia S.; Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer  2018,10,131-141","journal-title":"Breast Cancer"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"13672","DOI":"10.1038\/s41598-018-31939-9","volume":"8","author":"Taymaz-Nikerel H.","year":"2018","unstructured":"Taymaz-Nikerel H.; Karabekmez M.E.; Eraslan S.; K\u0131rdar B.; Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep  2018,8(1),13672","journal-title":"Sci Rep"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1159\/000492278","volume":"48","author":"Liu Y.","year":"2018","unstructured":"Liu Y.; Zhou H.; Ma X.; Lin C.; Lu L.; Liu D.; Ma D.; Gao X.; Qian X.Y.; Prodigiosin inhibits proliferation, migration, and invasion of nasopharyngeal cancer cells. Cell Physiol Biochem  2018,48(4),1556-1562","journal-title":"Cell Physiol Biochem"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S1174","volume":"4","author":"Cassier P.A.","year":"2008","unstructured":"Cassier P.A.; Dufresne A.; Blay J-Y.; Fayette J.; Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag  2008,4(1),109-116","journal-title":"Ther Clin Risk Manag"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1007\/s00018-009-0129-9","volume":"66","author":"Mogi T.","year":"2009","unstructured":"Mogi T.; Kita K.; Gramicidin S and polymyxins: The revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci  2009,66(23),3821-3826","journal-title":"Cell Mol Life Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s13018-019-1394-4","volume":"14","author":"Liu S.","year":"2019","unstructured":"Liu S.; Cao C.; Zhang Y.; Liu G.; Ren W.; Ye Y.; Sun T.; PI3K\/Akt inhibitor partly decreases TNF-\u03b1-induced activation of fibroblast-like synoviocytes in osteoarthritis. J Orthop Surg Res  2019,14(1),425","journal-title":"J Orthop Surg Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","volume":"107","author":"Hideshima T.","year":"2006","unstructured":"Hideshima T.; Catley L.; Yasui H.; Ishitsuka K.; Raje N.; Mitsiades C.; Podar K.; Munshi N.C.; Chauhan D.; Richardson P.G.; Anderson K.C.; Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood  2006,107(10),4053-4062","journal-title":"Blood"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s43587-022-00278-w","volume":"2","author":"Juricic P.","year":"2022","unstructured":"Juricic P.; Lu Y.X.; Leech T.; Drews L.F.; Paulitz J.; Lu J.; Nespital T.; Azami S.; Regan J.C.; Funk E.; Fr\u00f6hlich J.; Gr\u00f6nke S.; Partridge L.; Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy. Nature Aging  2022,2(9),824-836","journal-title":"Nature Aging"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"113353","DOI":"10.1016\/j.yexcr.2022.113353","volume":"420","author":"Zhang C.","year":"2022","unstructured":"Zhang C.; Wan J.; Liu Q.; Long F.; Wen Z.; Liu Y.; METTL3 upregulates COPS5 expression in osteosarcoma in an m6A-related manner to promote osteosarcoma progression. Exp Cell Res  2022,420(2),113353","journal-title":"Exp Cell Res"},{"key":"ref=144","first-page":"67","volume":"10","author":"Althobaiti N.A.","year":"2022","unstructured":"Althobaiti N.A.; Raza S.H.A.; The potential therapeutic role of camel milk exosomes. Ann Anim Sci  2022,10,67-91","journal-title":"Ann Anim Sci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12967-016-0814-z","volume":"14","author":"Babichev Y.","year":"2016","unstructured":"Babichev Y.; Kabaroff L.; Datti A.; Uehling D.; Isaac M.; Al-awar R.; Prakesch M.; Sun R.X.; Boutros P.C.; Venier R.; Dickson B.C.; Gladdy R.A.; PI3K\/AKT\/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J Transl Med  2016,14(1),67","journal-title":"J Transl Med"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/09553002.2021.1928786","volume":"97","author":"Rossetti A.","year":"2021","unstructured":"Rossetti A.; Petragnano F.; Milazzo L.; Vulcano F.; Macioce G.; Codenotti S.; Cassandri M.; Pomella S.; Cicchetti F.; Fasciani I.; Antinozzi C.; Di Luigi L.; Festuccia C.; De Felice F.; Vergine M.; Fanzani A.; Rota R.; Maggio R.; Polimeni A.; Tombolini V.; Gravina G.L.; Marampon F.; Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype. Int J Radiat Biol  2021,97(7),943-957","journal-title":"Int J Radiat Biol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1002\/jcb.26652","volume":"119","author":"Lien W.C.","year":"2018","unstructured":"Lien W.C.; Chen T.Y.; Sheu S.Y.; Lin T.C.; Kang F.C.; Yu C.H.; Kuan T.S.; Huang B.M.; Wang C.Y.; 7\u2010hydroxy\u2010staurosporine, UCN\u201001, induces DNA damage response, and autophagy in human osteosarcoma U2\u2010OS cells. J Cell Biochem  2018,119(6),4729-4741","journal-title":"J Cell Biochem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-01619-1_5","volume":"228","author":"Nesic K.","year":"2014","unstructured":"Nesic K.; Ivanovic S.; Nesic V.; Fusarial toxins: Secondary metabolites of Fusarium fungi. Rev Environ Contam Toxicol  2014,228,101-120","journal-title":"Rev Environ Contam Toxicol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3760\/cma.j.issn.1007-3418.2015.03.009","volume":"23","author":"Yao P.","year":"2015","unstructured":"Yao P.; Yang D.; Hu D.; Role of PI3K\/AKT pathways in mitomycin-mediated apoptosis of WB-F344 cells. Zhonghua Gan Zang Bing Za Zhi  2015,23(3),200-203","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1039\/D1OB02454J","volume":"20","author":"Heinil\u00e4 L.M.P.","year":"2022","unstructured":"Heinil\u00e4 L.M.P.; Jokela J.; Ahmed M.N.; Wahlsten M.; Kumar S.; Hrouzek P.; Permi P.; Koistinen H.; Fewer D.P.; Sivonen K.; Discovery of varlaxins, new aeruginosin-type inhibitors of human trypsins. Org Biomol Chem  2022,20(13),2681-2692","journal-title":"Org Biomol Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1517\/14728222.2013.733001","volume":"17","author":"Thomas S.","year":"2013","unstructured":"Thomas S.; Quinn B.A.; Das S.K.; Dash R.; Emdad L.; Dasgupta S.; Wang X.Y.; Dent P.; Reed J.C.; Pellecchia M.; Sarkar D.; Fisher P.B.; Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets  2013,17(1),61-75","journal-title":"Expert Opin Ther Targets"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/bbb\/zbab042","volume":"85","author":"Araki Y.","year":"2021","unstructured":"Araki Y.; Hanaki Y.; Kita M.; Hayakawa K.; Irie K.; Nokura Y.; Nakazaki A.; Nishikawa T.; Total synthesis and biological evaluation of oscillatoxins D, E, and F. Biosci Biotechnol Biochem  2021,85(6),1371-1382","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1055\/a-1045-5178","volume":"86","author":"Chilczuk T.","year":"2020","unstructured":"Chilczuk T.; Steinborn C.; Breinlinger S.; Zimmermann-Klemd A.M.; Huber R.; Enke H.; Enke D.; Niedermeyer T.H.J.; Gr\u00fcndemann C.; Hapalindoles from the cyanobacterium hapalosiphon sp. inhibit T cell proliferation. Planta Med  2020,86(2),96-103","journal-title":"Planta Med"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/ijms19030739","volume":"19","author":"Nakano K.","year":"2018","unstructured":"Nakano K.; Takahashi S.; Current molecular targeted therapies for bone and soft tissue sarcomas. Int J Mol Sci  2018,19(3),739","journal-title":"Int J Mol Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Liu Q.","year":"2023","unstructured":"Liu Q.; Li J.; Zheng H.; Yang S.; Hua Y.; Huang N.; Kleeff J.; Liao Q.; Wu W.; Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer  2023,22(1),28","journal-title":"Mol Cancer"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"106553","DOI":"10.1016\/j.phrs.2022.106553","volume":"187","author":"Paskeh M.D.A.","year":"2023","unstructured":"Paskeh M.D.A.; Ghadyani F.; Hashemi M.; Abbaspour A.; Zabolian A.; Javanshir S.; Razzazan M.; Mirzaei S.; Entezari M.; Goharrizi M.A.S.B.; Salimimoghadam S.; Aref A.R.; Kalbasi A.; Rajabi R.; Rashidi M.; Taheriazam A.; Sethi G.; Biological impact and therapeutic perspective of targeting PI3K\/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacol Res  2023,187,106553","journal-title":"Pharmacol Res"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"Hopkins B.D.","year":"2018","unstructured":"Hopkins B.D.; Pauli C.; Du X.; Wang D.G.; Li X.; Wu D.; Amadiume S.C.; Goncalves M.D.; Hodakoski C.; Lundquist M.R.; Bareja R.; Ma Y.; Harris E.M.; Sboner A.; Beltran H.; Rubin M.A.; Mukherjee S.; Cantley L.C.; Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature  2018,560(7719),499-503","journal-title":"Nature"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"Fakih M.G.","year":"2022","unstructured":"Fakih M.G.; Kopetz S.; Kuboki Y.; Kim T.W.; Munster P.N.; Krauss J.C.; Falchook G.S.; Han S.W.; Heinemann V.; Muro K.; Strickler J.H.; Hong D.S.; Denlinger C.S.; Girotto G.; Lee M.A.; Henary H.; Tran Q.; Park J.K.; Ngarmchamnanrith G.; Prenen H.; Price T.J.; Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol  2022,23(1),115-124","journal-title":"Lancet Oncol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575270904231129062137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225982\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575270904231129062137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T05:09:40Z","timestamp":1723180180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225982\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":158,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575270904231129062137","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}